Connection

W. Garvey to Blood Glucose

Back to Details
This is a "connection" page, showing publications W. Garvey has written about Blood Glucose.
W. Garvey
Connection Strength
4.300
Blood Glucose
  1. Development of a Weighted Cardiometabolic Disease Staging (CMDS) System for the Prediction of Future Diabetes. J Clin Endocrinol Metab. 2015 Oct; 100(10):3871-7.
    View in: PubMed
    Score: 0.390
  2. Use of HbA1c for diagnoses of diabetes and prediabetes: comparison with diagnoses based on fasting and 2-hr glucose values and effects of gender, race, and age. Metab Syndr Relat Disord. 2014 Jun; 12(5):258-68.
    View in: PubMed
    Score: 0.352
  3. Limitations in the use of indices using glucose and insulin levels to predict insulin sensitivity: impact of race and gender and superiority of the indices derived from oral glucose tolerance test in African Americans. Diabetes Care. 2013 Apr; 36(4):845-53.
    View in: PubMed
    Score: 0.325
  4. Canagliflozin extends life span in genetically heterogeneous male but not female mice. JCI Insight. 2020 11 05; 5(21).
    View in: PubMed
    Score: 0.140
  5. Development and validation of a model for predicting incident type 2 diabetes using quantitative clinical data and a Bayesian logistic model: A nationwide cohort and modeling study. PLoS Med. 2020 08; 17(8):e1003232.
    View in: PubMed
    Score: 0.138
  6. Efficacy and Safety of Liraglutide 3.0 mg in Individuals With Overweight or Obesity and Type 2 Diabetes Treated With Basal Insulin: The SCALE Insulin Randomized Controlled Trial. Diabetes Care. 2020 05; 43(5):1085-1093.
    View in: PubMed
    Score: 0.134
  7. Testosterone Therapy in Men With Hypogonadism Prevents Progression From Prediabetes to Type 2 Diabetes: Eight-Year Data From a Registry Study. Diabetes Care. 2019 06; 42(6):1104-1111.
    View in: PubMed
    Score: 0.125
  8. DYSGLYCEMIA-BASED CHRONIC DISEASE: AN AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS POSITION STATEMENT. Endocr Pract. 2018 Nov; 24(11):995-1011.
    View in: PubMed
    Score: 0.122
  9. Effects of canagliflozin versus glimepiride on adipokines and inflammatory biomarkers in type 2 diabetes. Metabolism. 2018 08; 85:32-37.
    View in: PubMed
    Score: 0.116
  10. Relationship of Circulating miRNAs with Insulin Sensitivity and Associated Metabolic Risk Factors in Humans. Metab Syndr Relat Disord. 2018 03; 16(2):82-89.
    View in: PubMed
    Score: 0.116
  11. Clinical implications of the insulin resistance syndrome. Clin Cornerstone. 1998; 1(3):13-28.
    View in: PubMed
    Score: 0.115
  12. Cardiometabolic Disease Staging Predicts Effectiveness of Weight-Loss Therapy to Prevent Type 2 Diabetes: Pooled Results From Phase III Clinical Trials Assessing Phentermine/Topiramate Extended Release. Diabetes Care. 2017 07; 40(7):856-862.
    View in: PubMed
    Score: 0.110
  13. Ablation of the Duodenal Mucosa as a Strategy for Glycemic Control in Type 2 Diabetes: Role of Nutrient Signaling or Simple Weight Loss. Diabetes Care. 2016 12; 39(12):2108-2110.
    View in: PubMed
    Score: 0.107
  14. Impact of lorcaserin on glycemic control in overweight and obese patients with type 2 diabetes: analysis of week 52 responders and nonresponders. Postgrad Med. 2016 Aug; 128(6):591-7.
    View in: PubMed
    Score: 0.104
  15. Trends in Cardiovascular Health Metrics in Obese Adults: National Health and Nutrition Examination Survey (NHANES), 1988-2014. J Am Heart Assoc. 2016 07 13; 5(7).
    View in: PubMed
    Score: 0.104
  16. AP2-NR4A3 transgenic mice display reduced serum epinephrine because of increased catecholamine catabolism in adipose tissue. Am J Physiol Endocrinol Metab. 2016 Jul 01; 311(1):E69-81.
    View in: PubMed
    Score: 0.103
  17. Deletion of the Toll-Like Receptor 5 Gene Per Se Does Not Determine the Gut Microbiome Profile That Induces Metabolic Syndrome: Environment Trumps Genotype. PLoS One. 2016; 11(3):e0150943.
    View in: PubMed
    Score: 0.102
  18. Cardiometabolic disease risk in metabolically healthy and unhealthy obesity: Stability of metabolic health status in adults. Obesity (Silver Spring). 2016 Feb; 24(2):516-25.
    View in: PubMed
    Score: 0.100
  19. Weight Loss and the Prevention and Treatment of Type 2 Diabetes Using Lifestyle Therapy, Pharmacotherapy, and Bariatric Surgery: Mechanisms of Action. Curr Obes Rep. 2015 Jun; 4(2):287-302.
    View in: PubMed
    Score: 0.096
  20. Weight-loss therapy in type 2 diabetes: effects of phentermine and topiramate extended release. Diabetes Care. 2014 Dec; 37(12):3309-16.
    View in: PubMed
    Score: 0.092
  21. The progression of cardiometabolic disease: validation of a new cardiometabolic disease staging system applicable to obesity. Obesity (Silver Spring). 2014 Jan; 22(1):110-8.
    View in: PubMed
    Score: 0.085
  22. Skeletal muscle lipid peroxidation and insulin resistance in humans. J Clin Endocrinol Metab. 2012 Jul; 97(7):E1182-6.
    View in: PubMed
    Score: 0.078
  23. Effects of colesevelam on glucose absorption and hepatic/peripheral insulin sensitivity in patients with type 2 diabetes mellitus. Diabetes Obes Metab. 2012 Jan; 14(1):40-6.
    View in: PubMed
    Score: 0.075
  24. Controlled-release phentermine/topiramate in severely obese adults: a randomized controlled trial (EQUIP). Obesity (Silver Spring). 2012 Feb; 20(2):330-42.
    View in: PubMed
    Score: 0.075
  25. Initial combination therapy with metformin and colesevelam for achievement of glycemic and lipid goals in early type 2 diabetes. Endocr Pract. 2010 Jul-Aug; 16(4):629-40.
    View in: PubMed
    Score: 0.069
  26. Colesevelam hydrochloride to treat hypercholesterolemia and improve glycemia in prediabetes: a randomized, prospective study. Endocr Pract. 2010 Jul-Aug; 16(4):617-28.
    View in: PubMed
    Score: 0.069
  27. A diabetes-specific enteral formula improves glycemic variability in patients with type 2 diabetes. Diabetes Technol Ther. 2010 Jun; 12(6):419-25.
    View in: PubMed
    Score: 0.068
  28. Effect of two carbohydrate-modified tube-feeding formulas on metabolic responses in patients with type 2 diabetes. Nutrition. 2008 Oct; 24(10):990-7.
    View in: PubMed
    Score: 0.060
  29. Ethnic heterogeneity in glucoregulatory function during treatment with atypical antipsychotics in patients with schizophrenia. J Psychiatr Res. 2008 Oct; 42(13):1076-85.
    View in: PubMed
    Score: 0.058
  30. Effects of short-term very low-calorie diet on intramyocellular lipid and insulin sensitivity in nondiabetic and type 2 diabetic subjects. Metabolism. 2008 Jan; 57(1):1-8.
    View in: PubMed
    Score: 0.058
  31. Polymorphism in the transcription factor 7-like 2 (TCF7L2) gene is associated with reduced insulin secretion in nondiabetic women. Diabetes. 2006 Dec; 55(12):3630-4.
    View in: PubMed
    Score: 0.053
  32. Critical evaluation of adult treatment panel III criteria in identifying insulin resistance with dyslipidemia. Diabetes Care. 2004 Apr; 27(4):978-83.
    View in: PubMed
    Score: 0.044
  33. Effects of insulin resistance and type 2 diabetes on lipoprotein subclass particle size and concentration determined by nuclear magnetic resonance. Diabetes. 2003 Feb; 52(2):453-62.
    View in: PubMed
    Score: 0.041
  34. Effective use of thiazolidinediones for the treatment of glucocorticoid-induced diabetes. Diabetes Res Clin Pract. 2002 Nov; 58(2):87-96.
    View in: PubMed
    Score: 0.040
  35. French-fried potato consumption and energy balance: a randomized controlled trial. Am J Clin Nutr. 2022 06 07; 115(6):1626-1636.
    View in: PubMed
    Score: 0.039
  36. Exercise training and diet-induced weight loss increase markers of hepatic bile acid (BA) synthesis and reduce serum total BA concentrations in obese women. Am J Physiol Endocrinol Metab. 2021 05 01; 320(5):E864-E873.
    View in: PubMed
    Score: 0.036
  37. CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM - 2020 EXECUTIVE SUMMARY. Endocr Pract. 2020 01; 26(1):107-139.
    View in: PubMed
    Score: 0.033
  38. CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM - 2019 EXECUTIVE SUMMARY. Endocr Pract. 2019 01; 25(1):69-100.
    View in: PubMed
    Score: 0.031
  39. APPLICATION OF THE AACE/ACE ADVANCED FRAMEWORK FOR THE DIAGNOSIS OF OBESITY AND CARDIOMETABOLIC DISEASE STAGING IN A GENERAL POPULATION FROM 3 REGIONS OF VENEZUELA: THE VEMSOLS STUDY RESULTS. Endocr Pract. 2018 Jan; 24(1):6-13.
    View in: PubMed
    Score: 0.029
  40. Exercise in transgenic mice overexpressing GLUT4 glucose transporters: effects on substrate metabolism and glycogen regulation. Metabolism. 1997 Nov; 46(11):1349-57.
    View in: PubMed
    Score: 0.028
  41. Muscle Rad expression and human metabolism: potential role of the novel Ras-related GTPase in energy expenditure and body composition. Diabetes. 1997 Mar; 46(3):444-50.
    View in: PubMed
    Score: 0.027
  42. Glucosamine induces insulin resistance in vivo by affecting GLUT 4 translocation in skeletal muscle. Implications for glucose toxicity. J Clin Invest. 1995 Dec; 96(6):2792-801.
    View in: PubMed
    Score: 0.025
  43. CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM--2015 EXECUTIVE SUMMARY. Endocr Pract. 2015 Dec; 21(12):1403-14.
    View in: PubMed
    Score: 0.025
  44. AACE/ACE comprehensive diabetes management algorithm 2015. Endocr Pract. 2015 Apr; 21(4):438-47.
    View in: PubMed
    Score: 0.024
  45. Enhanced adiponectin actions by overexpression of adiponectin receptor 1 in macrophages. Atherosclerosis. 2013 May; 228(1):124-35.
    View in: PubMed
    Score: 0.021
  46. Opportunities for using lipoprotein subclass profile by nuclear magnetic resonance spectroscopy in assessing insulin resistance and diabetes prediction. Metab Syndr Relat Disord. 2012 Aug; 10(4):244-51.
    View in: PubMed
    Score: 0.019
  47. Pretranslational suppression of an insulin-responsive glucose transporter in rats with diabetes mellitus. Science. 1989 Jul 07; 245(4913):60-3.
    View in: PubMed
    Score: 0.016
  48. Entero-insular axis and postprandial insulin differences in African American and European American children. Am J Clin Nutr. 2008 Nov; 88(5):1277-83.
    View in: PubMed
    Score: 0.015
  49. Day-long integrated serum insulin and C-peptide profiles in patients with NIDDM. Correlation with urinary C-peptide excretion. Diabetes. 1988 May; 37(5):590-9.
    View in: PubMed
    Score: 0.015
  50. Role of glucose transporters in the cellular insulin resistance of type II non-insulin-dependent diabetes mellitus. J Clin Invest. 1988 May; 81(5):1528-36.
    View in: PubMed
    Score: 0.015
  51. The effect of insulin treatment on insulin secretion and insulin action in type II diabetes mellitus. Diabetes. 1985 Mar; 34(3):222-34.
    View in: PubMed
    Score: 0.012
  52. Modulation of insulin secretion by insulin and glucose in type II diabetes mellitus. J Clin Endocrinol Metab. 1985 Mar; 60(3):559-68.
    View in: PubMed
    Score: 0.012
  53. Serum lipoproteins in the diabetes control and complications trial/epidemiology of diabetes intervention and complications cohort: associations with gender and glycemia. Diabetes Care. 2003 Mar; 26(3):810-8.
    View in: PubMed
    Score: 0.010
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.